Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, South Korea.
RMD Open. 2023 Mar;9(1). doi: 10.1136/rmdopen-2022-002874.
While many studies on the increased risk of cancer in patients with psoriasis are available, data on the risk of cancer in patients with psoriatic arthritis (PsA) are still scarce. We assessed the risk of cancer in patients with PsA in a nationwide population-based cohort in Korea.
From 2010 to June 2021, patients newly diagnosed with PsA and 1:10 age-matched and sex-matched controls were included in this study. The outcome was the incidence of overall and specific cancers.
Total 162 cancers occurred in 4688 PsA patients (incidence rate 83.2 (95% CI 70.8 to 97.0) per 10 000 person-years) and 1307 cancers occurred in 46 880 controls (incidence rate 66.9 (95% CI 63.3 to 70.6) per 10 000 person-years). The adjusted HR (aHR) of overall cancer in PsA patients was 1.20 (95% CI 1.02 to 1.41). However, this significance disappeared when non-melanoma skin cancer (NMSC) was excluded (aHR 1.16, 95% CI 0.98 to 1.37). Among specific cancers, the risk of NMSC (aHR 3.64 (95% CI 1.61 to 8.23)), lymphoma (aHR 2.63 (95% CI 1.30 to 5.30)) and thyroid cancer (aHR 1.83 (95% CI 1.18 to 2.85)) was higher in patients with PsA than in controls.
The risk of overall cancer was higher in patients with PsA than in the general population. Patients with PsA had increased risks of NMSC, lymphoma and thyroid cancer compared with the general population. Our findings suggest a need to conduct cancer screening by a detailed history and comprehensive clinical examination in patients with PsA.
虽然有许多关于银屑病患者癌症风险增加的研究,但关于银屑病关节炎(PsA)患者癌症风险的数据仍然很少。我们评估了韩国一项全国范围内基于人群的队列中 PsA 患者的癌症风险。
2010 年至 2021 年 6 月期间,纳入了新诊断为 PsA 的患者和年龄及性别相匹配的 1:10 对照组患者。结果为总体和特定癌症的发病率。
在 4688 例 PsA 患者中,共有 162 例癌症发生(发病率为 83.2(95%CI70.8 至 97.0)/10000 人年),在 46880 例对照组中,共有 1307 例癌症发生(发病率为 66.9(95%CI63.3 至 70.6)/10000 人年)。PsA 患者的总体癌症调整后的 HR(aHR)为 1.20(95%CI1.02 至 1.41)。然而,当排除非黑色素瘤皮肤癌(NMSC)时,这种显著性消失(aHR1.16,95%CI0.98 至 1.37)。在特定癌症中,NMSC(aHR3.64(95%CI1.61 至 8.23))、淋巴瘤(aHR2.63(95%CI1.30 至 5.30))和甲状腺癌(aHR1.83(95%CI1.18 至 2.85))的风险在 PsA 患者中高于对照组。
PsA 患者的总体癌症风险高于一般人群。与一般人群相比,PsA 患者患 NMSC、淋巴瘤和甲状腺癌的风险增加。我们的研究结果表明,需要对 PsA 患者进行详细病史和全面临床检查进行癌症筛查。